Our results further showed that CB agonist treatments of breast cancer cells also reduced the activation of NF-κB, which were involved in cancer-bone interaction, presumably by regulating the expression of inflammatory cytokines in breast cancer (as reviewed in Gordon et al.)46. Here, NFKB1 is linked to breast carcinoma.